Eli Lilly的阿尔茨海默氏病药物正在推动强劲的销售和增长,提高了其财务业绩和投资者信心。 Eli Lilly's Alzheimer’s drug is driving strong sales and growth, boosting its financial performance and investor confidence.

Eli Lilly和Co.看到其表现受到其老年痴呆症药物专卖权的极大影响,它已成为收入和增长的主要驱动力。 Eli Lilly and Co. is seeing its performance significantly influenced by its Alzheimer’s drug franchise, which has become a major driver of revenue and growth. 该公司对阿尔茨海默氏病的治疗,特别是最近经林业发展局批准的药物,在市场上获得了牵引力,促进了巨大的财政结果。 The company’s Alzheimer’s treatment, particularly its recent FDA-approved medication, has gained traction in the market, contributing to strong financial results. 这一成功表明,在一个治疗选择有限的疾病地区,对有效治疗的需求日益增加。 This success reflects growing demand for effective therapies in a disease area with limited treatment options. 随着人口老化,此类药物的潜在市场继续扩大,增强了投资者对莉莉长期前景的信心。 As the population ages, the potential market for such drugs continues to expand, bolstering investor confidence in Lilly’s long-term prospects.